Santhera Pharmaceuticals announced the voluntary withdrawal of Catena^® from the Canadian market. This decision follows review of additional data from clinical trials in patients with Friedreich’s Ataxia, and subsequent consultation with Health Canada. You can read the entire press release on Santhera’s website.